Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT04811872Phase 3Completed
Phase 3, randomised, open-label trial (3 arms). Primary endpoints: Superior Vena Cava Flow at 3 days, Fractional Shortening at 3 days and 5 more. Started Jan 2021; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT04811872.